U.S. regulators have approved Rasonque, Revolution Medicines’ experimental pancreatic cancer therapy, after the company submitted it for review on July 22 and secured clearance just over a month later through a special voucher that accelerates drug evaluations.
The approval lands at a striking moment: daraxonrasib, the drug now sold under the Rasonque brand, is the first therapy ever to push median survival past one year for pancreatic cancer patients in a Phase 3 clinical trial.
Patients receiving daraxonrasib in that pivotal trial survived a median of 13.2 months, compared with just 6.7 months for those treated with standard chemotherapy, representing a near-doubling of survival time.
The drug also cut the risk of death by 60% relative to chemotherapy, a margin that Revolution Medicines’ chief executive described as “unprecedented” and unlike anything previously demonstrated in a Phase 3 setting for this disease.
Chief development officer Alan Sandler underscored the historical weight of the data, noting it was the first time “any patients with pancreatic cancer” had lived a median of more than a year after receiving an experimental drug treatment in a clinical trial.
The results were also notable for their breadth: comparable survival benefits appeared even among patients who lacked the specific RAS G12 mutations that Revolution primarily targeted in its trial design.
Daraxonrasib works by broadly attacking RAS mutations, genetic drivers of tumor growth that are present in roughly 90% of pancreatic cancer cases, giving the drug a potentially wide patient base.
While drugs targeting a narrower KRAS mutation have already reached the market for certain lung and colorectal cancers, pancreatic tumors have been especially resistant to treatment partly because of how deeply they depend on RAS pathway activity.
The disease context makes these results all the more significant: pancreatic cancer carries the lowest five-year survival rate of any major cancer at just 13%, and around 80% of patients are not diagnosed until the disease has already spread, at which point five-year survival drops to approximately 3%.
Revolution Medicines (RVMD) shares surged roughly 39% on April 13, 2026, a single-day gain that added more than $7 billion to the company’s market capitalization and pushed its total valuation above $26 billion.
That rally capped a remarkable run for a company that went public at $17 per share in 2020 and has since seen its stock climb nearly ten-fold, giving it a market capitalization comparable to established biotech heavyweight Biogen.
Over the past year alone, RVMD shares have risen approximately 274%, propelled in part by persistent speculation that the company’s pipeline makes it an attractive acquisition candidate.
The Rasonque approval transforms Revolution from a high-potential clinical-stage bet into a commercial-stage biotech with a validated therapy for one of oncology’s most stubborn and lethal diseases.
